ANTIPROLIFERATIVE EFFECT AND SELECTIVITY OF SODIUM DICHLORO-BIS [N-PHENYL-5-CHLORO-SALICYLIDENEIMINATO-N, O] RUTHENATE (III) IN VITRO
Keywords:
Antiproliferative effect, Anticancer drugs, Ruthenium, Schiff bases, Selectivity, SW620Abstract
Ruthenium complexes attracted special attention in recent decades due to their anticancer properties. Since a number of Ru(III) complexes with Schiff bases showed moderate activity to bind DNA, antiproliferative effect of a chloro-ruthenium(III) complex which contains two O,N-bidentate Schiff bases derived from 5-chloro-salicylaldehyde was tested against cervical carcinoma, pancreatic carcinoma, hepatocellular carcinoma, metastatic lesions of colorectal adenocarcinoma and nontumoral cells WI38. The complex showed moderate antiproliferative properties in vitro and significant selectivity to SW620 metastatic lesions of colon cancer. Based on the positive research on ruthenium-based anticancer drugs and their generally moderate cytotoxicity in vitro (IC50) compared to platinum drugs which are in use, the titled compound might be a candidate for investigation in vivo, particularly to SW620.
Â
Downloads
References
He H, Pham-Huy L, Dramou P, Xiao D, Zuo P, Pham-Huy C. Carbon nanotubes: applications in pharmacy and medicine. Bio Med Res Int 2013;2013:1-12.
Clarke MJ, Bitler S, Rennert D, Buchbinder M, Kelman AD. Reduction and subsequent binding of ruthenium ions catalyzed by subcellular components. J Inorg Biochem 1980;12:79-87.
Kahrović E. Ruthenium compounds with Schiff bases: design and promising applications of salicylidenemine complexes. In: Keller GP, Editor. Ruthenium: Synthesis, Physicochemical Properties and Applications. 1st ed. New York: Nova Science Publishers Inc; 2014. p. 269-83.
Kahrovic E, Bektas S, Turkusic E, Zahirovic A. Evidence on antimicrobial activity of Sodium dichloro-bis[N-phenyl-5-chlorosalicylideneiminato-N,O]ruthenate(III) against gram-positive bacteria. SYLWAN 2104;158(5):482-93.
Ljubijankić N, Zahirović A, Turkušić E, Kahrović E. DNA binding properties of two ruthenium(iii) complexes containing schiff bases derived from salicylaldehyde: spectroscopic and electrochemical evidence of CT DNA intercalation. Croat Chem Acta 2013;86(2):215-22.
Gazivoda T, Raić-Malić S, Krištafor V, Makuc D, Plavec J, Bratulic S, et al. Synthesis, Cytostatic and Anti-HIV evaluations of the new unsaturated acyclic c-5 pyrimidine nucleoside analogues. Bioorg Med Chem 2008;16:5624–34.
Scolaro C, Bergamo A, Brescacin A, Delfino R, Cocchietto M, Laurenczy G, et al. Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death. J Med Chem 2005;48:4161–71.
Alessio E, Mestroni G, Bergamo A, Sava G. Ruthenium antimetastatic agents. Curr Top Med Chem 2004;4(15):1525–35.
Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem 2005;48(12):4161-71.
Zhang S, Lovejoy KS, Shima JE, Lagpacan L L, Shu Y, Lapuk A, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66(17):8847-57.
Keppler BK, Rupp W, Juhl UM, Endres H, Niebl R, Balzer W. Synthesis, molecular structure, and tumor-inhibiting properties of imidazolium trans-bis(imidazole)tetrachlororuthenate(III) and its methyl-substituted derivatives. Inorg Chem 1987;26(26):4366–70.
Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L. Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex. Int J Cancer 1996;68(1):60-6.